文献速递类风湿关节炎脊柱关节炎

第二剂SARS-CoV-2疫苗对类风湿关节炎和血清阴性脊柱关节炎患者实现血清学应答的重要性

Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
PubMed 文献 · Ann Rheum Dis · 2021-11-29

研究比较了53例类风湿关节炎、46例血清阴性脊柱关节炎患者与169名健康对照接种mRNA疫苗后的体液免疫应答。首剂后患者血清转化率仅54%,健康对照为98%;第二剂后所有组血清转化率均达100%。作者认为接受DMARD治疗的患者需完成两剂全程接种才能获得有效疫苗应答。

要点

  • 首剂mRNA疫苗后炎症性关节炎患者血清转化率仅54%,健康对照为98%。
  • 第二剂后所有组血清转化率均达100%,抗体滴度与健康对照无差异。
  • DMARD联合治疗者血清转化率和滴度水平较健康对照降低。

核心结论

  • 接受DMARD治疗的炎症性关节病患者对首剂mRNA疫苗的体液应答受损,但完成两剂后最终应答良好。
  • 作者认为接受DMARD治疗的炎症性关节炎患者需要完成两剂全程接种才能获得有效疫苗应答。

研究设计与样本

  • 纳入类风湿关节炎和血清阴性脊柱关节炎患者,排除接受B细胞耗竭治疗者,评估mRNA疫苗首剂和第二剂后血清转化率与滴度的体液应答。
  • 结果与健康对照组比较,并分析治疗及其他特征对体液应答的影响。
  • 分析样本来自53例类风湿关节炎患者、46例脊柱关节炎患者和169名健康参与者。

主要发现

  • 首剂免疫后炎症性关节炎患者血清转化率仅54%,健康对照组为98%。
  • 第二剂免疫后所有组血清转化率均为100%。
  • 首剂疫苗后患者抗体滴度较健康对照降低,但第二剂后无差异。
  • DMARD单药治疗不影响抗体水平。
  • 接受DMARD联合治疗的患者血清转化率及滴度水平较健康对照降低。

临床怎么用

  • 作者认为接受DMARD治疗的炎症性关节炎患者需要完成两剂mRNA疫苗全程接种以获得有效疫苗应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the kinetics of humoral response after the first and second dose of messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases compared with healthy controls (HC). To analyse factors influencing the quantity of the immune response. METHODS: We enrolled patients with rheumatoid arthritis (RA) and seronegative spondyloarthritis (SpA), excluding those receiving B-cell depleting therapies and assessed the humoral response to mRNA vaccines after the first and the second dose of the vaccine in terms of seroconversion rate and titre. We compared the results to a HC group and analysed the influence of therapies as well as other characteristics on the humoral response. RESULTS: Samples from 53 patients with RA, 46 patients with SpA and 169 healthy participants were analysed. Seroconversion rates after the first immunisation were only 54% in patients with inflammatory arthritis compared with 98% in the HC group. However, seroconversion rates were 100% in all groups after second immunisation. Patients developed reduced antibody titres after the first vaccination compared with HC, but there was no difference after the second dose. While disease modifying anti-rheumatic drug (DMARD) monotherapy did not affect antibody levels, seroconversion rates as well as titre levels were reduced in patients receiving a combination of DMARDs compared with HC. CONCLUSIONS: Patients with inflammatory joint diseases under DMARD therapy show impaired humoral responses to the first vaccine dose but excellent final responses to vaccination with mRNA vaccines. Therefore, the full course of two immunisations is necessary for efficient vaccination responses in patients with inflammatory arthritis under DMARD therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Simader E, Tobudic S, Mandl P, et al. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Ann Rheum Dis. 2021. PMID: 34844927. doi:10.1136/annrheumdis-2021-221347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。